Life Sciences Artificial Intelligence
Protecting Innovation at the Intersection of AI & Life Sciences
Artificial intelligence (AI) is transforming the development of new and more effective therapeutics, increasing accuracy and speed of diagnosis, enabling discovery of new drugs and treatment modalities, and opening pathways to create everyday goods using engineered biologic and chemical compounds. Steeped in the life sciences and high technology, Mintz’s designated team of AI-focused IP practitioners — immunologists, microbiologists, chemists, physicists, computer scientists, and electrical engineers — works collaboratively with clients innovating at the intersection of AI and life sciences. We work with scientists, entrepreneurs, and executives to help them protect their market-leading positions, and with the investors who infuse this sector with capital.
Share Awards
Patexia
Ranked as the Top 10 Most Active Law Firm for Biotech Patents (Patexia, 2024).
Managing Intellectual Property
Life Sciences practice ranked nationally among top firms, ten attorneys named to IP Stars list and one named as a recognized practitioner (2023)
LMG Life Sciences
Firm ranked nationally for Patent Prosecution and Patent Strategy & Management in LMG Life Sciences - Americas (2023)
IAM Patent 1000
10 attorneys + MA Patent Litigation and CA Patent practices recognized (2021)
Chambers USA
Four attorneys recognized as leading CA & MA IP practitioners. Practice Chair recognized as ITC Patent Litigation Practitioner (2021)
Best Lawyers in America
11 attorneys recognized as “Best Lawyers” in 4 IP practice areas (2020)
Our Approach
The Mintz Life Sciences AI team represents companies at the cutting-edge of modern science. With the application of AI and machine learning, our clients are revolutionizing day-to-day operations for scientists, clinicians, and inventors by improving odds for disease diagnosis, speeding up the potential for drug discovery, enhancing results of clinical trials, enabling more efficient targeting of therapeutics, and clearing the way for more innovative uses of biologic and chemical compounds in the production of everyday goods.
We conduct invention disclosure meetings with scientists to help identify patentable innovations and inventions and work with legal counsel and business executives to develop global patent strategies to create valuable IP portfolios.
We work with investors to conduct rigorous IP diligence on technology involving both AI and life sciences to identify and mitigate risks while providing recommendations for strengthening the IP portfolios in which they invest.
- Biochemistry
- Cellular and Molecular Medicine
- Chemistry
- Molecular Biology
- Physics
- Electrical Engineering
- Computer Science
- Mechanical Engineering
- Software Development
- Portfolio analysis
- Competitive landscaping
- Invention assessment and identification
- Patent drafting and prosecution
- Overcoming 101 rejections
- Strategic portfolio development
- Trade Secret strategy
- Software copyrighting
- Work for hire counseling
- Inventorship counseling
- IP policy development
- Licensing and other transactions
- Due diligence
- Patent and Trade Secret litigation
- Bioinformatics
- Cloud computing
- Data analysis
- Data mining and engineering
- Data security and privacy
- Diagnostics and biomarkers
- Dosing
- Distributed computing
- Gene editing
- Genomics
- Image analysis
- Immunology
- Machine learning
- Natural language processing
- Patient monitoring
- Pattern recognition
- Proteins
- Regenerative medicine
We are fortunate to be a patent practice within a full-service law firm that has a reputation for industry-focused knowledge. We work with our colleagues across practices to ensure that clients get advice that meets their business goals and strengthens their competitive positions. From trademarks to transactions to trade secrets, we’ve got you covered.
Meet Mintz
The Mintz AI in Life Sciences Team is a dedicated team of AI-focused IP practitioners with backgrounds in immunology, microbiology, chemistry, physics, computer science, and electrical engineering working collaboratively with clients innovating at the intersection of AI and life sciences.
Our Insights
Viewpoints
FDA Needs a New Approach to AI/ML-Enabled Medical Devices
March 12, 2024| Blog|
